Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | PIK3CA |
Variant | C420R |
Impact List | missense |
Protein Effect | gain of function |
Gene Variant Descriptions | PIK3CA C420R lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). C420R confers a gain of function on Pik3ca, as indicated by constitutive phosphorylation of downstream targets Akt and S6, increased cell proliferation and migration, and is transforming in cell culture (PMID: 17376864, PMID: 29533785, PMID: 34779417). |
Associated Drug Resistance | |
Category Variants Paths |
PIK3CA mutant PIK3CA act mut PIK3CA C420R PIK3CA mutant PIK3CA exon8 PIK3CA C420R |
Transcript | NM_006218.4 |
gDNA | chr3:g.179210192T>C |
cDNA | c.1258T>C |
Protein | p.C420R |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_011512894 | chr3:g.179210192T>C | c.1258T>C | p.C420R | RefSeq | GRCh38/hg38 |
NM_006218 | chr3:g.179210192T>C | c.1258T>C | p.C420R | RefSeq | GRCh38/hg38 |
XM_006713658 | chr3:g.179210192T>C | c.1258T>C | p.C420R | RefSeq | GRCh38/hg38 |
XM_011512894.2 | chr3:g.179210192T>C | c.1258T>C | p.C420R | RefSeq | GRCh38/hg38 |
XM_006713658.4 | chr3:g.179210192T>C | c.1258T>C | p.C420R | RefSeq | GRCh38/hg38 |
NM_006218.4 | chr3:g.179210192T>C | c.1258T>C | p.C420R | RefSeq | GRCh38/hg38 |
NM_006218.3 | chr3:g.179210192T>C | c.1258T>C | p.C420R | RefSeq | GRCh38/hg38 |
XM_006713658.5 | chr3:g.179210192T>C | c.1258T>C | p.C420R | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05154487 | Phase II | Alpelisib + Fulvestrant | A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer | Recruiting | USA | 0 |
NCT05455619 | Phase Ib/II | Capivasertib + Fulvestrant + SDX-7320 Alpelisib + Fulvestrant + SDX-7320 | Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Women With a PI3K Alteration and HR+/Her2- Breast Cancer (Amelia-1) | Recruiting | USA | 0 |